RecruitMe Clinical Trial

Combination Ruxolitinib and Decitabine in patients with Myeloproliferative Neoplasms in Accelerated and Blast Phase Disease
Study of Effectiveness of Ruxolitinib in combination with Decitabine in Patients with Myeloproliferative Neoplasms (MPN)
Sponsor:Myeloproliferative Disorders Research Consortium
Enrolling:Male and Female Patients
IRB Number:AAAO0959
U.S. Government ID:NCT02076191
Contact: Mark Heaney MD: 646-317-5077 / mlh2192@cumc.columbia.edu
Additional Study Information:

The purpose of this phase I study is to test the safety and tolerability of ruxolitinib at different dose levels in combination with decitabine in patients with accelerated or blast phase Myeloproliferative Neoplasm (MPN), which is a group of diseases of the bone marrow in which excess cells are produced. You may qualify to take part in this research study because you have a MPN blood disorder called myelofibrosis (MF), essential thrombocythemia (ET), or polycythemia vera (PV) that is accelerated or blast phase.The purpose of this phase II study is to test the effectiveness of ruxolitinib in combination with decitabine in patients with accelerated or blast phase Myeloproliferative Neoplasm (MPN), which is a group of diseases of the bone marrow in which excess cells are produced. A fixed dose of ruxolitinib that was determined to be safe in the phase I portion of this study will be used in combination with decitabine in this phase II portion of the study.

This study is closed
Investigator
Mark Heaney, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Mark Heaney MD
Email: mlh2192@cumc.columbia.edu
Phone: 646-317-5077